



HAL
open science

Honeydew honey as a potent antibacterial agent in eradication of multi-drug resistant *Stenotrophomonas maltophilia* isolates from cancer patients

Juraj Majtan, Lubica Majtanova, Jana Bohova, Viktor Majtan

► **To cite this version:**

Juraj Majtan, Lubica Majtanova, Jana Bohova, Viktor Majtan. Honeydew honey as a potent antibacterial agent in eradication of multi-drug resistant *Stenotrophomonas maltophilia* isolates from cancer patients. *Phytotherapy Research*, 2010, 25 (4), pp.584. 10.1002/ptr.3304 . hal-00599844

HAL Id: hal-00599844

<https://hal.science/hal-00599844>

Submitted on 11 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Honeydew honey as a potent antibacterial agent in eradication of multi-drug resistant *Stenotrophomonas maltophilia* isolates from cancer patients

Journal:	<i>Phytotherapy Research</i>
Manuscript ID:	PTR-10-0640.R2
Wiley - Manuscript type:	Full Paper
Date Submitted by the Author:	12-Jul-2010
Complete List of Authors:	Majtan, Juraj; Institute of Zoology Slovak Academy of Sciences; Slovak Medical University, Department of Microbiology Majtanova, Lubica; Slovak Medical University, Department of Microbiology Bohova, Jana; Institute of Zoology, Slovak Academy of Sciences Majtan, Viktor; Slovak Medical University, Department of Microbiology
Keyword:	<i>Stenotrophomonas maltophilia</i> , honey, multi-drug resistance, antibacterial, manuka, honeydew



1
2
3 **Honeydew honey as a potent antibacterial agent in eradication of multi-drug resistant**
4
5 ***Stenotrophomonas maltophilia* isolates from cancer patients**
6
7

8
9
10 **Short title:** Honey in eradication of multi-drug resistant *S. maltophilia*
11
12

13
14
15 Juraj Majtan^{1,2*}, Lubica Majtanova², Jana Bohova¹ and Viktor Majtan²
16
17

18
19
20 ¹Institute of Zoology, Slovak Academy of Sciences, Dubravská cesta 9, 845 06 Bratislava,
21
22 Slovakia
23

24
25 ²Department of Microbiology, Slovak Medical University, Limbova 12, 833 03, Bratislava,
26
27 Slovakia
28

29
30
31
32
33
34 * Correspondence to: Dr. Juraj Majtan, Institute of Zoology, Slovak Academy of Sciences,
35
36 Dubravská cesta 9, 845 06 Bratislava, Slovakia, Tel.: +421-2-59302647, Fax.: +421-2-59302646,
37
38 E-mail address: Juraj.Majtan@savba.sk
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Multi-drug resistance in nosocomial pathogens is a continually evolving and alarming problem in health care units. Since ancient times, honey has been used successfully for treatment of broad spectrum of infections with no risk of resistance development.

In this study, we investigated the antibacterial activity of two natural honeys, namely honeydew and manuka, against 20 nosocomial multi-drug resistant *Stenotrophomonas maltophilia* (*S. maltophilia*) isolates from cancer patients. Antibiotic susceptibility test was carried out using disk diffusion method with 20 antibiotic disks. The antibacterial activity of honey was determined using a broth dilution method. The concentration of honey used in study was within the range of 3.75% to 25% (w/v). All 20 clinical isolates were multi-drug resistant against 11 to 19 antibiotics. The MICs for honeydew honey ranged from 6.25% to 17.5%, while those for active manuka honey ranged from 7.5% to 22.5%. Honeydew honey had the lower MICs than manuka honey against 16 of tested isolates.

This study showed that Slovak honeydew honey has exceptional antibacterial activity against multi-drug resistant *S. maltophilia* isolates and was more efficient than manuka honey (UMF 15+). Honeydew honey with strong antibacterial activity could be used as a potential agent to eradicate of multi-drug resistance clinical isolates.

Keywords: honey, *Stenotrophomonas maltophilia*, multi-drug resistance, antibacterial, manuka, honeydew

Introduction

Nowadays, *Stenotrophomonas maltophilia* has been considered, as an important opportunistic nosocomial pathogen in immune-competent individuals associated with different diseases that include both acute and chronic infections. Especially susceptible to *S. maltophilia* are immune-compromised patients, for example, patients with cancer (Khardori *et al.*, 1990; Paez and Costa, 2008). *S. maltophilia* infection in hospitalized patients with cancer has significantly increased over the past two decades (Safdar and Rolston, 2007).

Very recent studies have revealed that *S. maltophilia* originating from external environment, the enteric tract or respiratory secretion may also participate in pathogenesis of persistent infections, particularly in chronic mucosal of skin surface infections (Dowd *et al.*, 2008; Guggenheim *et al.*, 2009; Tan *et al.*, 2009). It has been found that incidence of *S. maltophilia* in burn wounds markedly increased in last decade (Guggenheim *et al.*, 2009). In addition, Dowd *et al.* (2008) showed that *S. maltophilia* was a predominant bacterial type in biofilm associated with venous leg ulcers.

A characteristic feature of *S. maltophilia* is its low susceptibility to most agents currently used for treatment of human infections (Looney *et al.*, 2009). Moreover, *S. maltophilia* exhibits high-level resistance to a variety of structurally unrelated antibiotics, including β -lactams, quinolones, aminoglycosides, tetracycline, disinfectants and heavy metals (Zhang *et al.*, 2000). The treatment of choice for *S. maltophilia* infections is still co-trimoxazole alone, or in combination with other agents. However, isolates resistant to this agent have already been reported (Nicodemo and Paez, 2007; Vartivarian *et al.*, 1994). The increasing lack of antimicrobials with activity against *S. maltophilia* is of concern and there is an urgent need for new drugs.

1
2
3 With increasing frequency modern medicine directs attention to natural products with
4 antimicrobial activity and their use in clinical practice. The major arguments for implementing
5 natural products such as honey are the low cost and absence of antimicrobial resistance risk.
6
7
8 Honey can inhibit the growth wide range o bacteria, fungi, protozoa and viruses (Blair and
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

With increasing frequency modern medicine directs attention to natural products with antimicrobial activity and their use in clinical practice. The major arguments for implementing natural products such as honey are the low cost and absence of antimicrobial resistance risk. Honey can inhibit the growth wide range o bacteria, fungi, protozoa and viruses (Blair and Carter, 2005; Molan, 1992). Manuka honey derived from the floral source of *Leptospermum scoparium* in New Zealand has been claimed to have particularly high antimicrobial activity against various bacterial species (Allen *et al.*, 1991; Lin *et al.*, 2009; Lusby *et al.*, 2005; Molan, 2006).

Beside two well-characterized major antibacterial factors in honey, hydrogen peroxide and high osmolarity; methylglyoxal (Adams *et al.*, 2008; Mavric *et al.*, 2008) and bee defensin-1 (Kwakman *et al.*, 2010) also act as antibacterial substances. In addition, phenolic compounds found in dark honeys are partially responsible for antibacterial activity (Aljadi and Yusoff, 2003; Estevinho *et al.*, 2008; Wahdan, 1998).

In our study, we investigate the antibacterial effect of Slovak honeydew honey against 20 nosocomial multi-drug *S. maltophilia* isolates from cancer patients and compare it with the activity of manuka honey.

Materials and Methods

Bacterial isolates

1
2
3 *S. maltophilia* clinical isolates (n = 20) from cancer patients were received from Department of
4 Clinical Microbiology of National Institute for Oncology (Bratislava, Slovakia). These clinical
5 isolates were collected during the period from December 2003 to March 2004.
6
7
8
9

10 11 12 13 **Honey samples** 14 15 16

17 The antibacterial activity of Slovak honeydew honey against 20 nosocomial clinical isolates of *S.*
18 *maltophilia* was determined by comparison to the commercially available active manuka honey
19 imported from New Zealand (Natur's Nectar, UMF 15+). Honeydew honey used in this study is
20 monofloral honey derived from the floral source of *Abies spp.* localized in Bardejov (Slovakia)
21 and was obtained from an apiary of Mr. Jozef Volansky (Medar s.r.o., Bardejov, Slovakia).
22
23
24
25
26
27
28

29 To distinguish the effect of the antibacterial components of honey from any osmotic effect,
30 artificial honey, a control solution with sugar content similar to that of natural honey, was also
31 used for comparison. The artificial honey was prepared by dissolving 39 g D-fructose, 31 g D-
32 glucose, 8 g maltose, 3 g sucrose and 19 g distilled water. All honey samples were stored in
33 darkness at 2-5°C when not in use.
34
35
36
37
38
39

40 Fifty percent (w/v) stock solution of each type of honey was prepared by weighing 20 g of honey
41 and bringing the volume up to 40 ml of Trypton soya broth (TSB). Further dilutions of stock
42 solution of natural honeys were done to obtain honey concentrations of 25%, 22.5%, 20%,
43 17.5%, 15%, 12.5%, 11.25%, 10%, 8.75%, 7.5%, 6.25%, 5% and 3.75%. Dilution range of 50%,
44 25% and 12.5% of artificial honey was used.
45
46
47
48
49
50
51

52 53 54 55 **Antibiotic susceptibility test** 56 57

1
2
3
4
5
6 Antibiotic susceptibility was determined by the disk diffusion method with 20 antibiotic disks
7
8 according to the criteria of the Clinical and Laboratory Standards Institute (CLSI) (Clinical and
9
10 Laboratory Standards Institute, 2005) on Mueller-Hinton (MH) agar (Oxoid, Hampshire, UK).
11
12 The following antimicrobial agents (disk content indicated in parentheses) were tested:
13
14 amoxicillin-clavulanic acid (20/10 µg), ampicillin (10 µg), aztreonam (30 µg), cefepime (30 µg),
15
16 cefotaxime (30 µg), ceftazidime (30 µg), ceftriaxone (30 µg), cefepime (30 µg),
17
18 cefotaxime (30 µg), ceftazidime (30 µg), ceftriaxone (30 µg), chloramphenicol (30 µg),
19
20 ciprofloxacin (5 µg), cloxacillin (5 µg), gentamicin (10 µg),
21
22 nalidixic acid (30 µg), piperacillin-tazobactam (100/10 µg), streptomycin (10 µg), tetracycline
23
24 (30 µg), trimethoprim (5 µg), sulfisoxazole (250 µg) trimethoprim-sulfamethoxazole (1.25/23.75
25
26 µg), *E. coli* ATCC 25922 was used as the control.
27
28
29
30
31

32 **Minimum inhibitory concentration assay**

33
34
35

36 Determination of MIC was conducted according to the recommendation of the CLSI (Clinical
37
38 and Laboratory Standards Institute, 2003) with minor modification of using TSB instead of MH
39
40 broth. Briefly, one bacterial colony was suspended in PBS buffer, pH 7.2 and the turbidity of
41
42 suspension was adjusted to 10^8 colony forming unit (cfu)/mL and diluted with medium to final
43
44 concentration of 10^7 cfu/mL. Ten µl aliquots of suspension were inoculated to each well of
45
46 sterile 96-well polystyrene plates (Sarstedt, Germany). The final volume in each well was 100
47
48 µL, consisting of 90 µL of sterile medium or diluted honey and 10 µL of bacterial suspension.
49
50
51 After 18 h of incubation at 37°C, bacterial growth inhibition was determined by monitoring the
52
53
54
55
56
57
58
59
60

1
2
3 optical density at 490 nm. The MIC was defined as the lowest concentration of antibiotic
4
5 inhibiting bacterial growth. All tests were performed in triplicate and were repeated three times.
6
7
8
9

10 **Results**

11 **Antibiotic susceptibility testing**

12
13
14
15
16
17
18
19
20 All 20 clinical isolates were multi-drug resistant against 11 to 19 antibiotics. Among all isolates,
21
22 four strains (20%) were resistant against co-trimoxazole (trimethoprim-sulfamethoxazole). The
23
24 resistance against co-trimoxazole was associated with isolates resistant at least to 15 antibiotics.
25
26 Ciprofloxacin resistance was found in two isolates (10%). Antimicrobial resistance profiles of all
27
28 isolates are summarized in Table 1.
29
30
31
32
33

34 **Determination of MIC of honey**

35
36
37
38
39 The MIC values of the two natural honeys and artificial honey are shown in Table 2. The MICs
40
41 for honeydew honey ranged from 6.25% to 17.5%, while those for active manuka honey ranged
42
43 from 7.5% to 22.5%. Honeydew honey had the lower MICs than manuka honey against 16 of
44
45 tested *S. maltophilia* isolates, where the MIC values of honeydew honey were below 10% in 14
46
47 isolates. No difference was observed in the antibacterial activity of both natural honeys against
48
49 two isolates. Artificial honey inhibited the growth of all isolates at concentration higher than
50
51 25%.
52
53
54
55
56
57
58
59
60

Discussion

S. maltophilia has emerged as an important pathogen, whose eradication is often problematic due to resistance to broad spectrum of antibiotics. When the administration of co-trimoxazole for the treatment of patients with *S. maltophilia* infections is not possible, there may be other effective alternative treatments using ciprofloxacin as a monotherapy or in combination with other antibiotics, or ticarcillin-clavulanate alone or in combination with other agents. An increasing trend of resistance to ciprofloxacin and emerging co-trimoxazole resistance in *S. maltophilia* was reported in last decade (Gales *et al.*, 2001; San Gabriel *et al.*, 2004). We found that 20% of isolates used in this study were resistant to co-trimoxazole, an agent still recommended for treatment of *S. maltophilia* infections. In addition, 10% of isolates exhibited the resistance to ciprofloxacin, as a second therapeutic option. Novel or re-emerged antibacterial agents are urgently needed for treatment of infections caused by multi-drug resistant *S. maltophilia*. Honey could be a potential natural candidate to help eradicate of *S. maltophilia* infections.

It has been demonstrated that medical-grade manuka honey is effective against broad range of microorganisms including multi-resistant clinical strains (George and Cutting, 2007). Until now, it has not been shown that honey is able to inhibit the growth of multi-drug clinical *S. maltophilia* isolates. However, Tan *et al.* (2009) demonstrated that Malaysian tualang honey together with manuka honey (UMF 10+) with MIC of 10% (w/v) showed good antibacterial activity against *S. maltophilia* clinical strain with unknown antibiotic susceptibility profile.

Both Medihoney, a medical grade manuka honey and Revamil, a medical grade buckwheat honey are well-characterized honeys with pronounced healing properties. It has been documented that antibacterial activity of manuka honey directly originates from the

1
2
3 methylglyoxal (Adams *et al.*, 2008; Mavric *et al.*, 2008). On the other hand, antibacterial bee
4
5 defensin-1 has very recently been identified in Revamil and it substantially contributes to the
6
7 antibacterial activity of honey (Kwakman *et al.*, 2010). It remains to establish whether
8
9 methylglyoxal and antibacterial bee peptide are also present in other natural honeys.
10
11

12
13 Along with methylglyoxal and defensin-1, the phenolic compounds in honey have been
14
15 considered as potential antimicrobial agents (Gomez-Caravaca *et al.*, 2006; Taormina *et al.*,
16
17 2001). The honey phenolic compounds composition and consequent antibacterial and antioxidant
18
19 capacity of honey depends on their floral sources. In present study, dark honeydew honey
20
21 derived from the floral source of *Abies spp.* was used to investigate its bactericidal activity
22
23 against multi-drug resistant *S. maltophilia* isolates. According to recent studies (Estevinho *et al.*,
24
25 2008; Kwakman *et al.*, 2010), we speculate that several non-peroxide factors, namely defensin-1
26
27 and phenolic compounds of honeydew honey participate in its strong antibacterial properties.
28
29 Further detailed studies are needed to identification of components responsible for antibacterial
30
31 properties of honeydew honey.
32
33
34
35

36
37 In conclusion, our results document that Slovak honeydew honey has exceptional antibacterial
38
39 activity against multi-drug resistant *S. maltophilia* isolates from cancer patients. In addition, in
40
41 the most cases it exhibited considerably stronger antibacterial activity than manuka honey and it
42
43 could potentially be used as an alternative therapeutic agent against *S. maltophilia* infections.
44
45
46
47

48 **Acknowledgements**

49
50
51
52

53 We thank Mrs. Janka Zatkova for her technical assistance. This work was funded by the
54
55 Operational Program Research and Development and co-financed with European Fund for
56
57

1
2
3 Regional Development (EFRD). Grant: ITMS 26240220020 – “Establishment of biotherapeutic
4 facility and technology proposal for production and development of bio-drugs”.
5
6
7
8
9

10 References

- 11
12
13
14
15 1. Adams CJ, Boulton CH, Deadman BJ, Farr JM, Grainger MNC, Manley-Harris M, Snow MJ.
16
17 2008. Isolation by HPLC and characterisation of the bioactive fraction of New Zealand
18
19 manuka (*Leptospermum scoparium*) honey. *Carbohydr Res* **343**: 651-659.
20
21
- 22 2. Aljadi AM, Yusoff KM. 2003. Isolation and identification of phenolic acids in Malaysian
23
24 honey with antibacterial properties. *Turk J Med Sci* **33**: 229-236.
25
26
- 27 3. Allen KL, Molan PC, Reid GM. 1991. A survey of the antibacterial activity of some New
28
29 Zealand honeys. *J Pharm Pharmacol* **43**: 817-822.
30
31
- 32 4. Blair SE, Carter DA. 2005. The potential for honey in the management of wounds and
33
34 infections. *J Australian Infect Control* **10**: 24-31.
35
36
- 37 5. Clinical and Laboratory Standards Institute. 2003. Methods for dilution of antimicrobial
38
39 susceptibility tests for bacteria that growth aerobically, 6th edn. Approved standard M7-A6.
40
41 *CLSI/NCCLS M7-A6 Wayne (PA): The Institute.*
42
43
- 44 6. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial
45
46 susceptibility testing; 15th informational supplement. *CLSI/NCCLS M100-S15 Wayne (PA):*
47
48 *The Institute.*
49
50
- 51 7. Dowd SE, Sun Y, Secor PR, Rhoads DD, Wolcott BM, James GA, Wolcott RD. 2008. Survey
52
53 of bacterial diversity in chronic wounds using Pyrosequencing, DGGE, and full ribosome
54
55 shotgun sequencing. *BMC Microbiol* **8**: 1-15.
56
57

- 1
2
3 8. Estevinho L, Pereira AP, Moreira L, Dias LG, Pereira E. 2008. Antioxidant and antimicrobial
4 effects of phenolic compounds extracts of Northeast Portugal honey. *Food Chem Toxicol* **46**:
5
6 3774-3779.
7
8
- 9
10 9. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. 2001. Emerging
11 importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas maltophilia*
12 as pathogens in seriously ill patients: geographic patterns, epidemiological features, and
13 trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). *Clin Infect Dis* **32**:
14
15 S104-S132.
16
17
- 18 10. George NM, Cutting KF. 2007. Antibacterial honey (MedihoneyTM): in vitro activity against
19 clinical isolates of MRSA, VRE and other multiresistant gram-negative organisms including
20
21 *Pseudomonas aeruginosa*. *Wounds* **19**: 231-236.
22
23
- 24 11. Gomez-Caravaca AM, Gomez-Romero M, Arraez-Roman D, Segura-Carretero A,
25
26 Fernandez-Gutierrez A. 2006. Advances in the analysis of phenolic compounds in products
27 derived from bees. *J Pharm Biomed Anal* **41**: 1220-1234.
28
29
- 30 12. Guggenheim M, Zbinden R, Handschin AE, Gohritz A, Altintas MA, Giovanoli P. 2009.
31
32 Changes in bacterial isolates from burn wounds and their antibiograms: A 20-year study
33
34 (1986-2005). *Burns* **35**: 553-560.
35
36
- 37 13. Khardori N, Elting L, Wong E, B S, Bodey GP. 1990. Nosocomial infections due to
38
39 *Xanthomonas maltophilia* (*Pseudomonas maltophilia*) in patients with cancer. *Rev Infect Dis*
40
41 **12**: 997-1003.
42
43
- 44 14. Kwakman PH, te Velde AA, De Boer L, Speijer D, Vandenbroucke-Grauls CM, Zaat SA.
45
46
47
48
49
50
51 2010. How honey kills bacteria. *FASEB J* **24**: in press.
52
53
54
55
56
57

15. Lin SM, Molan PC, Cursons RT. 2009. The in vitro susceptibility of *Campylobacter spp.* to the antibacterial effect of manuka honey. *Eur J Clin Microbiol Infect Dis* **28**: 339-344.
16. Looney WJ, Narita M, Muhlemann K. 2009. *Stenotrophomonas maltophilia*: an emerging opportunistic human pathogen. *Lancet Infect Dis* **9**: 312-323.
17. Lusby PE, Coombes AL, Wilkinson JM. 2005. Bactericidal activity of different honeys against pathogenic bacteria. *Arch Med Res* **36**: 464-467.
18. Mavric E, Wittmann S, Barth G, Henle T. 2008. Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (*Leptospermum scoparium*) honeys from New Zealand. *Mol Nutr Food Res* **52**: 483-489.
19. Molan PC. 1992. The antibacterial nature of honey. 1. The nature of the antibacterial activity. *Bee World* **73**: 5-28.
20. Molan PC. 2006. The evidence supporting the use of honey as a wound dressing. *Int J Low Extrem Wounds* **5**: 40-54.
21. Nicodemo AC, Paez JI. 2007. Antimicrobial therapy for *Stenotrophomonas maltophilia* infections. *Eur J Clin Microbiol Infect Dis* **26**: 229-237.
22. Paez JI, Costa SF. 2008. Risk factors associated with mortality of infections caused by *Stenotrophomonas maltophilia*: a systematic review. *J Hosp Infect* **70**: 101-108.
23. Safdar A, Rolston KV. 2007. *Stenotrophomonas maltophilia*: changing spectrum of a serious bacterial pathogen in patients with cancer. *Clin Infect Dis* **45**: 1602-1609.
24. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. 2004. Antimicrobial susceptibility and synergy studies of *Stenotrophomonas maltophilia* isolates from patients with cystic fibrosis. *Antimicrob Agents Chemother* **48**: 168-171.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Tan HT, Rahman RA, Gan SH, Halim AS, Hassan SA, Sulaiman SA, Kirnpal-Kaur B. 2009. The antibacterial properties of Malaysian tualang honey against wound and enteric microorganisms in comparison to manuka honey. *BMC Complement Altern Med* **9**: 34.
26. Taormina PJ, Niemera BA, Beuchat LR. 2001. Inhibitory activity of honey against foodborne pathogens as influenced by the presence of hydrogen peroxide and level of antioxidant power. *Int J Food Microbiol* **69**: 217-225.
27. Vartivarian SE, Anaissie EJ, Bodey GP, Sprigg H, Rolston KV. 1994. A changing pattern of susceptibility of *Xanthomonas maltophilia* to antimicrobial agents: implications for therapy. *Antimicrob Agents Chemother* **38**: 624-627.
28. Wahdan HA. 1998. Causes of the antimicrobial activity of honey. *Infection* **26**: 26-31.
29. Zhang L, Li XZ, Poole K. 2000. Multiple antibiotic resistance in *Stenotrophomonas maltophilia*: involvement of a multidrug efflux system. *Antimicrob Agents Chemother* **44**: 287-293.

Table 1. Incidence of antibiotic resistance in 20 clinical isolates of *S. maltophilia*

Isolate	Antibiogram
No. (n=20)	
57/03	A AMC ATM CPD CRO CTX FEP FOX OB TMP TZP
58/03	A AMC ATM C CAZ CPD CRO CTX FEP FOX NAL OB S Su SXT TMP TZP
122/03	A AMC ATM CPD CRO CTX FEP FOX NAL OB S Su TMP TZP
241/03	A AMC ATM CAZ CPD CRO CTX FEP FOX OB TMP TZP
255/03	A AMC ATM C CIP CPD CRO CTX FEP FOX G NAL OB S Su SXT T TMP TZP
269/03	A AMC ATM CPD CRO CTX FEP FOX OB TMP TZP
325/03	A AMC ATM C CAZ CIP CPD CRO CTX FEP FOX G NAL OB S Su SXT T TMP
368/03	A AMC ATM CPD CRO CTX FEP FOX OB Su TMP TZP
388/03	A AMC ATM C CPD CRO CTX FEP FOX OB TMP TZP
389/03	A AMC ATM CAZ CPD CRO CTX FEP FOX OB TMP TZP
509/03	A AMC ATM CPD CRO CTX FEP FOX OB TMP TZP
996/03	A AMC ATM CPD CRO CTX FEP FOX NAL OB TMP TZP
1444/03	AMC ATM CAZ CPD CRO CTX FEP FOX OB Su TMP TZP
3354/03	A AMC ATM CPD CRO CTX FEP FOX OB TMP TZP
47/04	A AMC ATM CPD CRO FEP FOX OB S Su TMP TZP
287/04	A AMC ATM CAZ CPD CRO CTX FEP FOX OB S Su TMP TZP
300/04	A AMC ATM C CAZ CPD CRO CTX FEP FOX OB Su SXT TMP TZP
846/04	A AMC ATM CPD CRO CTX FEP FOX OB Su TMP TZP
993/04	A AMC ATM CPD CRO CTX FEP FOX OB Su TMP TZP

999/04

A AMC ATM CPD CRO CTX FEP FOX OB TMP TZP

A, ampicillin; AMC, amoxicillin-clavulanic acid; ATM; aztreonam; C, chloramphenicol; CAZ, ceftazidime; CIP, ciprofloxacin; CPD, cefpodoxime; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; FOX, cefoxitin; G, gentamicin; OB, cloxacillin; NAL, nalidixic acid; S, streptomycin; Su, sulfisoxazole; SXT, trimethoprim-sulfamethoxazole; T, tetracycline; TMP, trimethoprim; TZP, piperacillin-tazobactam

For Peer Review

Table 2. Minimum inhibitory concentration (%) of different honeys towards *S. maltophilia* clinical isolates

<i>S. maltophilia</i> strain (n=20)	Type of honey		
	Honeydew	Manuka (UMF 15+)	Artificial
57/03	7.5	15	50
58/03	7.5	15	25
122/03	7.5	11.25	50
241/03	7.5	15	25
255/03	10	20	50
269/03	7.5	15	50
325/03	8.75	17.5	50
368/03	7.5	15	50
388/03	7.5	11.25	25
389/03	6.25	11.25	25
509/03	7.5	15	25
996/03	7.5	15	25
1444/03	7.5	15	50
3354/03	7.5	15	50
47/04	12.5	11.25	50
287/04	8.75	11.25	25
300/04	11.25	7.5	25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

846/04	15	10	50
993/04	17.5	17.5	50
994/04	17.5	17.5	50

For Peer Review